PUBLICATIONS

First Author

1. Yoshimoto S, Kato D, kamoto S, Yamamoto K, Tsuboi M, Shinada M, Ikeda N, Tanaka Y, Yoshitake R, Eto S, Saeki K, Chambers J, Hashimoto Y, Uchida K, Nishimura R, Nakagawa T. Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer. The Journal of Veterinary Medical Science, 82 (6), 804-808, 2020.
2. Yoshimoto S, Kato D, Kamoto S, Yamamoto K, Tsuboi M, Shinada M, Ikeda N, Tanaka Y, Yoshitake R, Eto S, Saeki K, Chambers J, Kinoshita R, Uchida K, Nishimura R, Nakagawa T. Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma. Heliyon, 5 (7), e02004, 2019.
3. Yoshimoto S, Kato D, Kamoto S, Yamamoto K, Tsuboi M, Shinada M, Ikeda N, Tanaka Y, Yoshitake R, Eto S, Saeki K, Chambers J, Kinoshita R, Uchida K, Nishimura R, Nakagawa T. Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma. The Journal of Veterinary Medical Science, 81 (7), 1034-1039, 2019.
4. Kiname K*, Yoshimoto S*, Kato D, Tsuboi M, Tanaka Y, Yoshitake R, Eto S, Shinada M, Chambers J, Saeki K, Kinoshita R, Yamada S, Uchida K, Kaneko M, Nishimura R, Kato Y, Nakagawa T. Evaluation of immunohistochemical staining with PMab-38, an anti-dog podoplanin monoclonal antibody, in various canine tumor tissues. Japanese Journal of Veterinary Research, 67 (1), 25-34, 2019. *Kiname K and Yoshimoto S equally contributed as first author.
5. Yoshimoto S, Hoshino Y, Izumi Y, Takagi S. α-Smooth muscle actin expression in cancer-associated fibroblasts in canine epithelial tumors. Japanese Journal of Veterinary Research, 65 (3), 135-144, 2017.

Co-author

1. Kida T, Yamazaki A, Nakamura T, Kobayashi K, Yoshimoto S, Maeda S, Nakagawa T, Nishimura R, Murata T. Comprehensive profiling of lipid metabolites in urine of canine patients with liver mass. The Journal of Veterinary Medical Science, 84 (8):1074-1078, 2022.
2. Kudo A, Yoshimoto S, Yoshida H, Izumi Y, Takagi S. Biological features of canine cancer-associated fibroblasts and their influence on cancer cell invasion. The Journal of Veterinary Medical Science, 84 (6):784-791, 2022.
3. Mason NJ, Chester N, Xiong A, Rotolo A, Wu Y, Yoshimoto S, Glassman P, Gulendran G, Siegel DL. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors. mAbs, 2004638, 2021.
4. Ikeda N, Kato D, Tsuboi M, Yoshitake R, Eto S, Yoshimoto S, Shinada M, Kamoto S, Hashimoto Y, Takahashi Y, Chambers J, Uchida K, Nichimura R, Nakagawa T. Detection of indoleamine 2,3-dioxygenase 1-expressing cells in canine normal and tumor tissues. The Journal of Veterinary Medical Science, 83 (12), 1885-890, 2021.
5. Kamoto S, Shinada M, Kato D, Tsuboi M, Yoshimoto S, Yoshitake R, Eto S, Ikeda N, Takahashi Y, Hashimoto Y, Chambers J, Uchida K, Yamada S, Kaneko MK, Nishimura R, Kato Y, Nakagawa T. The expression of podoplanin in various types of feline tumor tissues. The Journal of Veterinary Medical Science, 83 (11),1795-1799, 2021.
6. Shinada M, Saeki K, Yoshitake R, Eto S, Tsuboi M, Chambers JK, Uchida K, Kato D, Yoshimoto S, Kamoto S, Ikeda N, Kinoshita R, Fujita N, Nishimura R, Nakagawa T. Evaluation of epithelial and mesenchymal cell markers in canine urinary bladder transitional cell carcinoma. The Veterinary Journal, 266, 105571. 2020.
7. Kamoto S, Shinada M, Kato D, Yoshimoto S, Ikeda N, Tsuboi M, Yoshitake R, Eto S, Hashimoto Y, Takahashi Y, Chambers J, Uchida K, Kaneko MK, Fujita N, Nishimura R, Kato Y, Nakagawa T. Phase I/II clinical trial of the anti-podoplanin monoclonal antibody therapy in dogs with malignant melanoma. Cells, 9 (11), 2529, 2020.
8. Shinada M, Kato D, Kamoto S, Yoshimoto S, Tsuboi M, Yoshitake R, Eto S, Ikeda N, Saeki K, Hashimoto Y, Takahashi Y, Chambers J, Uchida K, Kaneko M, Fujita N, Nishimura R, Kato Y, Nakagawa T. PDPN is expressed in various types of canine tumors and its silencing induces apoptosis and cell cycle arrest in canine malignant melanoma. Cells, 9 (5), 1136, 2020.
9. Eto S, Saeki K, Yoshitake R, Yoshimoto S, Shinada M, Ikeda N, Kamoto S, Tanaka Y, Kato D, Maeda S, Tsuboi M, Chambers J, Uchida K, Nishimura R, Nakagawa T. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells. PLoS One, 14 (6), e0218382, 2019.

ORAL PRESENTATIONS

Lead Presenter

1. Yoshimoto S, Rotolo A, Takagi S, Mason NJ. Successful expression of a PD-1-CD28 switch receptor to overcome PD-L1 mediated inhibition of canine CAR-T cells. The Annual Conference of the Veterinary Cancer Society, Norfolk, VA, USA, October 2022.
2. Yoshimoto S, Kasper B, Rotolo A, Nakagawa T, Takagi S, Mason NJ. Developing and evaluating CAR-T cells for use in canine cancer patients to inform human clinical translation. 81^st Annual Meeting of the Japanese Cancer Association, Kanagawa, Japan, September 2022
3. Yoshimoto S, Haran KP, Covo M, Mason NJ. Optimizing genetically modified T cell function for durable remission of canine lymphoma. The 1st ToBeST symposium, Seoul, Korea, November 2019.
4. Yoshimoto S, Haran KP, Covo M, Mason NJ. Comparison of different intracellular signaling domains in canine chimeric antigen receptor T cells. The Annual Conference of the Veterinary Cancer Society, Houston, TX, USA, October 2019.

POSTER PRESENTATIONS

Lead Presenter

1. Yoshimoto S, Rotolo A, Mason NJ. A PD-1/CD28 switch receptor augments canine CAR-T cell function against PD-L1 expressing target cells. Annual Faculty Research Retreat at University of Pennsylvania, Philadelphia, USA, October 2022.
2. Yoshimoto S, Rotolo A, Takagi S, Mason NJ. PD-1/CD28 switch receptor overcome PD-L1 mediated inhibition of canine CAR-T cells. 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology, Online USA, September 2022.
3. Yoshimoto S, Rotolo A, Mason NJ. A PD-1/CD28 switch receptor augments canine CAR-T cell function against PD-L1 expressing target cells. Annual Faculty Research Retreat at University of Pennsylvania, Philadelphia, USA, October 2022.
4. Yoshimoto S, Chester N, Xiong A, Gulendran G, Siegel D, Raedelli E, Mason NJ. Development of a canine anti-canine PD-1 antibody fragment to enhance CART efficiency in solid tumours. The Annual Conference of the Veterinary Cancer Society, Online, USA, November 2021.
5. Yoshimoto S, Chester N, Xiong A, Rotolo A, Gulendran G, Raedelli E, Siegel D, Mason NJ. Development of a canine anti-canine PD-1 antibody fragment to enhance Chimeric Antigen Receptor-T cell efficiency. Annual Faculty Research Retreat at University of Pennsylvania, Philadelphia, USA, October 2021.
6. Yoshimoto S, Haran KP, Covo M, Mason NJ. Comparison of different intracellular signaling domains in canine CAR T cells. Annual Faculty Research Retreat at University of Pennsylvania, Philadelphia, USA, June 2019.
7. Yoshimoto S, Kato D, Yamamoto K, Kamoto S, Tsuboi M, Shinada M, Ikeda N, Tanaka Y, Yoshitake R, Eto S, Chambers J, Saeki K, Kinoshita R, Uchida K, Nishimura R, Nakagawa T. Overexpression of HER2 in canine anal sac adenocarcinoma. The Annual Conference of the Veterinary Cancer Society, Louisville, KY, USA, October 2018.
8. Yoshimoto S, Hoshino Y, Aoshima K, Izumi Y, Yoshida H, Takagi S. Isolation of cancer-associated fibroblasts from canine anal sac adenocarcinoma. The Sixth Annual Congress of Asian Society of Veterinary Surgery Meeting, Fukuoka, Japan, December 2016.

POSTER PRESENTATIONS

Co-presenter

1. Kudo A, Yoshimoto S, Yamauchi A, Yoshida H, Kanai E, Kamiie J, Takagi S. Evaluating the interaction between canine cancer-associated fibroblasts and CD8⁺ T cells via CXCL12-CXCR4 axis. The Annual Conference of the Veterinary Cancer Society, Norfolk, VA, USA, October 2022.
2. Kiname K, Kato D, Yoshimoto S, Tanaka Y, Yoshitake R, Eto S, Shinada M, Tsuboi M, Chambers J, Uchida K, Saeki K, Kaneko MK, Nakagawa T, Kato Y, Nishimura R. Detection of tumor specific expression of podoplanin by PMab-38 in various tumors. Annual Conference of Veterinary Cancer Society, Oregon, USA, October 2017.

COMPETITIVE RESEARCH FUNDING

1. Grant-in-Aid for Early-Career Scientists, JP22K15018, Investigation of exhaustion-inducing factors and the mechanisms of exhaustion in canine chimeric antigen receptor T cells, April 2022 – March 2024.
2. Grant-in-Aid for JSPS Fellows, JP21J01155, Development of canine chimeric antigen receptor-T cell that converts exhaustion-inducing signals into activation signals, April 2021 – March 2024.
3. Grant-in-Aid for JSPS Fellows, JP19J12763, Engineering chimeric antigen receptor T cells targeting cancer cells and cancer associated fibroblasts. April 2019 – March 2021.

AWARDS

1. Best Poster 3rd Place at Penn Vet’s Annual Faculty Research Retreat, June 2019.

OTHER ACTIVITY (Startup)

1. Pre-Founders Program, FoundX, University of Tokyo, (Tokyo, Japan) October 2020 – March 2021
2. Incubation, Innovation Platform for The University of Tokyo, (Tokyo, Japan) January 2021 – June 2021
3. Best award in Entrepreneur Challenge 2022, Lead Presenter, University of Tokyo, September 2020.